DelveInsight has released its comprehensive report on the Chronic Spontaneous Urticaria (CSU) market, detailing key epidemiological data, treatment trends, and market dynamics across major global regions.
Market Size and Growth Projections
As of 2022, the Chronic Spontaneous Urticaria market was valued at USD 2,084 million and is expected to exhibit significant growth with a compound annual growth rate (CAGR) throughout the study period from 2020 to 2034. The United States emerged as the dominant market, holding a 53% share, surpassing EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan combined.
Regulatory Developments
In October 2023, the US Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab), aimed at treating adolescents and adults with inadequately controlled CSU using H1 antihistamines.
Epidemiological Insights
DelveInsight’s analysis in 2022 identified approximately 4,154,234 diagnosed prevalent cases of chronic urticaria across the seven major markets. Within these, 68% were categorized as CSU, while the remainder fell under other classifications like Chronic Inducible Urticaria (CIndU).
Gender Disparities
Across EU4 and the UK, females were predominantly affected by CSU, with notable figures in Germany showing 229,935 female cases compared to 97,142 males in 2022. Similar trends were observed in the United States, with 379,253 female cases versus 138,004 male cases.
Therapeutic Landscape and Pipeline
Key companies driving advancements in CSU treatments include Novartis, Sanofi/Regeneron, Amgen, and others. Therapies such as Ligelizumab, Dupixent, and Tezepelumab are among those leading the market uptake, with promising pipeline candidates like Remibrutinib and CDX-0159 undergoing development.
Market Drivers and Barriers
Factors such as treatment side effects, economic burdens on patients, and intensified research and development activities are anticipated to bolster market growth. Conversely, challenges like the complex understanding of disease pathology and approaching patent expiries may impede progress.
Future Outlook
The Chronic Spontaneous Urticaria market is poised for expansion, driven by increasing disease prevalence and heightened awareness. Ongoing advancements in therapeutic innovation are expected to reshape market dynamics, offering new hope for patients globally.
Conclusion
DelveInsight’s detailed analysis underscores the evolving landscape of Chronic Spontaneous Urticaria, highlighting pivotal market trends, therapeutic breakthroughs, and regulatory milestones shaping the future of CSU management.
For more insights into the Chronic Spontaneous Urticaria market, including comprehensive epidemiological data and therapeutic advancements, DelveInsight’s report offers a crucial resource for stakeholders navigating this dynamic sector.
This rewritten article adheres to professional standards, presenting key information in a structured and informative manner while maintaining fidelity to the original content’s intent and details.
Related Topics:
